Sequana Medical - Additional positive data from MOJAVE
Sequana Medical announced positive data for the third patient enrolled in the non-randomized cohort in MOJAVE (heart failure program). These results are in line with those from the two other patients enrolled in that cohort published mid-October.The independent Data Safety Monitoring Board will now review the data from this non-randomized cohort. Upon their approval - expected in Q1 24 - the enrollment of the entire 30-patients randomized cohort will start. Top line results are then foreseen by H2 24.Positive news but no material impact. Given the early development stage of the program with only a limited number of patients enrolledSequana Medical NV. Sequana Medical NV is a Belgium-based company, which manufactures medical devices. The Company focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.